SCHEMBL14368134

SCHEMBL14368134

O=C(NCc1ccccc1)c1csc(-c2ccnc(O)c2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ TLR7 Q9NYK1 4/20 0.53
▸ HDAC1 Q13547 1/20 0.52
▸ HDAC8 Q9BY41 1/20 0.52
▸ HDAC6 Q9UBN7 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.50
▸ MMP13 P45452 1/20 0.50
▸ CDC7 O00311 1/20 0.49
▸ CCNE1 P24864 1/20 0.49
▸ CDK2 P24941 1/20 0.49
▸ DBF4 Q9UBU7 1/20 0.49
▸ EGFR P00533 1/20 0.49
▸ ROCK2 O75116 1/20 0.48
▸ GRK2 P25098 1/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12790089 0.86 HPGD (0.69) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL14368136 0.85 HPGD (0.51) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL17175809 0.80 IRAK4 (0.69) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL3366715 0.79 EGLN1 (0.69) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL1569133 0.74 SMN1; SMN2 (0.67) HPGDHDAC1HDAC8HDAC6MMP13
SCHEMBL27306159 0.74 HPGD (0.62) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL20508211 0.74 WNT3A (0.52) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL20726555 0.73 SMN1; SMN2 (0.56) HPGDCYP1A2CYP2C9CYP2C19HDAC1
SCHEMBL12789158 0.73 HPGD (0.69) HPGDCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL14368126 0.73 PKM (0.56) HPGDCYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 — — EP disclosed
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof CAO JINGRONG 2007-11-15 — — US disclosed
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof CAO JINGRONG 2007-11-15 — — US disclosed
US-7253187-B2 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-07 — — US disclosed
US-7253187-B2 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAPKAPK2 HPGD 709/4885CYP1A2 1890/4885CYP3A4 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback